Groothuis J R
Department of Pediatrics, University of Colorado School of Medicine, Denver.
Pediatr Infect Dis J. 1994 May;13(5):454-7; discussion 457-8. doi: 10.1097/00006454-199405000-00038.
Respiratory syncytial virus (RSV) is the only viral respiratory pathogen that produces an annual epidemic of respiratory illness. Infants with cardiac disease or infants born prematurely with or without bronchopulmonary dysplasia are at increased risk of severe RSV disease. A recently developed RSV immunoglobulin (RSVIG) was studied to determine safety and efficacy in prevention of severe RSV disease in such children who are high risk for severe RSV illness. Results from this prospective, blinded trial involving 249 children (102 with broncho-pulmonary dysplasia, 87 with congenital heart disease and 60 who were born prematurely) indicate that high dose RSVIG reduced the incidence and severity of RSV lower respiratory tract infection. It is a safe and effective means of RSV prophylaxis in selected high risk children.
呼吸道合胞病毒（RSV）是唯一一种每年都会引发呼吸道疾病流行的病毒性呼吸道病原体。患有心脏病的婴儿或早产的婴儿，无论有无支气管肺发育不良，患严重RSV疾病的风险都会增加。一项针对最近研发的RSV免疫球蛋白（RSVIG）进行的研究，旨在确定其在预防此类严重RSV疾病高危儿童患严重RSV疾病方面的安全性和有效性。这项涉及249名儿童（102名患有支气管肺发育不良、87名患有先天性心脏病、60名早产）的前瞻性双盲试验结果表明，高剂量RSVIG可降低RSV下呼吸道感染的发生率和严重程度。这是在选定的高危儿童中预防RSV的一种安全有效的方法。
